1. Volume 104, Pages 119-125 (February 2017)
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC 
Yi-Long Wu, Nagahiro Saijo, Sumitra Thongprasert, J. C.-H. Yang, Baohui Han, Benjamin Margono, Busayamas Chewaskulyong, Patrapim Sunpaweravong, Yuichiro Ohe, Yukito Ichinose, Jin-Ji Yang, Tony S.K. Mok, Helen Young, Vincent Haddad, Yuri Rukazenkov, Masahiro Fukuoka 
Lung Cancer 
Volume 104, Pages (February 2017)
DOI: /j.lungcan
Copyright © 2016 The Authors Terms and Conditions

2. Fig. 1 Patient disposition (CONSORT diagram).
Lung Cancer  , DOI: ( /j.lungcan )
Copyright © 2016 The Authors Terms and Conditions

3. Fig. 2
A. PFS by original IPASS investigator-assessment (EGFR mutation-positive ITT population). B. PFS by BICR (EGFR mutation-positive ITT population).
Lung Cancer  , DOI: ( /j.lungcan )
Copyright © 2016 The Authors Terms and Conditions

4. Fig. 3
A. PFS by BICR (EGFR mutation-positive ITT population) − exon 19 deletion. B. PFS by BICR (EGFR mutation-positive ITT population) − L858R mutation.
Lung Cancer  , DOI: ( /j.lungcan )
Copyright © 2016 The Authors Terms and Conditions